Moleculin's $8.3 Million Cash Grab Came With a Catch — Can a Micro-Cap Biotech Survive Doubling Its Share Count?

Shares of Moleculin Biotech (MBRX) plunged 19.4% to $2.88 as the lingering shadow of a February 2026 warrant deal continues to crush investor confidence. The Houston-based clinical-stage drugmaker raised quick cash — but at a price that may cost shareholders far more in the long run.

$8.3 Million Bought Time, but the Bill Keeps Growing. Back in February, Moleculin struck agreements for warrant holders to immediately exercise warrants for up to 2,122,652 shares at $3.90 each, generating roughly $8.3 million in gross proceeds. That sounds like a lifeline — until you see the sweetener: the company issued new warrants covering up to 6,367,956 additional shares, subject to shareholder approval, with a five-year term.

Those new warrants carry a lower exercise price of just $2.3976 per share — well below where the stock traded at the time. For every dollar raised today, the company promised to potentially hand out three times as many shares tomorrow.

The Math Is Brutal: More New Shares Than Currently Exist. The warrant exercise volume exceeds the company's roughly 4.9 million shares currently outstanding, representing potential dilution that fundamentally alters the capital structure.

Shareholders approved the issuance at an April 15 special meeting , clearing the final hurdle. If fully exercised, the share count could more than double — meaning each existing share's claim on future profits or a buyout gets sliced in half.

Cash Runway Is Thin Despite the Raise. MBRX held about $10.3 million in cash last quarter but burned through a $12.8 million net loss in the same period.

With only 17 employees, that's an outsized burn rate , suggesting the $8.3 million buys roughly one to two quarters of breathing room at best — and the market clearly expects more dilutive raises ahead.

The Trial Is the Only Lifeline. Moleculin's pivotal Phase 3 trial for its lead cancer drug in relapsed leukemia has enrolled 45 patients, with an interim data readout expected mid-2026.

H.C. Wainwright maintains a $22 price target — a staggering gap from today's $2.88. But that target hinges entirely on clinical success. If the data disappoints, the stock has almost no floor given the dilution overhang and zero revenue. The warrant deal traded long-term ownership for short-term survival — and today's selloff shows the market hasn't forgiven that trade.